Stifel lowered the firm’s price target on Insmed (INSM) to $96 from $97 and keeps a Buy rating on the shares. With mid-year Phase 2 PAH data for TPIP and year-end Phase 2b CRSsNP data for brensocatib, the firm continues to view FY25 as “a critical year for the company,” the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Strong 2024 Growth and Promising Pipeline
- Ritu Baral’s Buy Rating for Insmed Supported by Strong Financials and Promising Pipeline
- Insmed Board Member Alfred Altomari to Step Down
- Insmed reports Q4 EPS ($1.32), consensus ($1.16)
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
Questions or Comments about the article? Write to editor@tipranks.com